Atrial tachycardia is a heart rhythm disorder characterized by an increased heart rate originating from an ectopic atrial focus, distinct from the sinoatrial node. The rhythm may be regular or, in some forms, irregular, thus falling under the definition of arrhythmia. This condition can present as a paroxysmal form, with self-limited episodes, or as a persistent form, lasting for prolonged periods. Its clinical significance depends on the frequency and duration of episodes, the presence of underlying heart disease, and the ventricular response.
The underlying causes can be classified into structural alterations, modifications of the autonomic nervous system, and metabolic and electrolyte factors. Each of these conditions can alter the propagation of the electrical impulse in the atria, leading to the development of tachycardia.
Structural alterations, such as ischemic heart disease, valvular diseases, and cardiomyopathies, result in remodeling of the atrial myocardium, with the formation of fibrosis and electrical conduction inhomogeneity. This pathological substrate creates an environment favorable to the activation of reentrant circuits and the development of ectopic foci with abnormal automaticity. Chronic lung diseases, such as COPD and pulmonary hypertension, also contribute to atrial remodeling, inducing right atrial dilation and altering the normal balance between sympathetic and vagal tone.
In addition to structural factors, modifications of the autonomic nervous system play a key role in the pathogenesis of atrial tachycardia. Excessive adrenergic stimulation, as occurs in stress, hyperthyroidism, or feverish states, increases the excitability of atrial cells, facilitating the appearance of ectopic activity. Conversely, reduced vagal modulation can impair the control mechanisms of the sinoatrial node, favoring the prevalence of independent atrial foci.
Metabolic and electrolyte alterations also contribute to the development of atrial tachycardia. Imbalances in potassium, magnesium, and calcium levels alter the membrane potential of myocardial cells, affecting the duration of refractory periods and predisposing to the generation of abnormal impulses. Hypokalaemia, in particular, prolongs the atrial refractory period, increasing the risk of focal tachycardias, while hypercalcaemia may facilitate late afterdepolarizations, promoting triggered activity.
From a pathophysiological perspective, atrial tachycardia can be sustained by three main mechanisms:
These mechanisms may coexist and vary depending on the patient’s clinical condition. Identifying the specific cause and predominant mechanism is essential to determine the most effective therapeutic strategy, whether pharmacological or ablative.
The development of atrial tachycardia is favored by a number of predisposing factors that alter the electrical stability of the myocardium or modify its response to stimuli. Identifying these factors is essential for prevention and management of the disorder.
The main risk factors include:
Clinically, atrial tachycardia may present variably depending on heart rate, episode duration, and ventricular response. In individuals with a healthy heart, it may be asymptomatic or associated with mild symptoms, whereas in patients with heart disease it can result in haemodynamic instability.
The most common symptoms include:
In more severe cases, atrial tachycardia can promote the onset of heart failure, especially if the ventricular response is very high and not adequately controlled. Prompt recognition of symptoms and correct assessment of their severity are essential to set up an adequate therapeutic strategy.
During the examination, the physical assessment may reveal signs indicative of atrial tachycardia and any associated conditions. The most common findings include:
In patients with paroxysmal episodes, the physical examination may be normal outside the tachycardia phases. For this reason, diagnostic confirmation requires ECG or prolonged electrocardiographic monitoring.
The suspicion of atrial tachycardia arises from the history and analysis of the symptoms reported by the patient. Definitive diagnosis is based on instrumental tests able to characterize the rhythm alteration and distinguish atrial tachycardia from other types of supraventricular tachyarrhythmias.
The first examination to be performed is the electrocardiogram (ECG), which allows identification of the distinctive features of atrial tachycardia.
The main findings include:
In patients with intermittent or short-duration episodes, Holter monitoring is an essential investigation to document the presence of tachycardia during the day, evaluate its duration, and the ventricular response.
In some cases, when there is suspicion of a relationship between tachycardia and physical exertion, an exercise test is performed to determine the role of adrenergic stimulation in its onset. This test is particularly useful in patients whose tachycardia occurs mainly during stress or intense physical activity.
When the diagnosis remains uncertain or a form of atrial tachycardia refractory to drug therapy is suspected, electrophysiological study (EPS) may be indicated. This invasive procedure allows mapping of the ectopic focus responsible for the arrhythmia and assessment of the possibility of treatment by transcatheter ablation.
Differential diagnosis should consider other supraventricular tachycardias, such as AV nodal reentrant tachycardia or atrioventricular reentrant tachycardia, as well as atrial arrhythmias such as atrial flutter or atrial fibrillation with rapid ventricular response. Accurate clinical and instrumental evaluation is essential to distinguish atrial tachycardia from these conditions and to set up the most appropriate therapeutic strategy.
The management of atrial tachycardia depends on the severity of symptoms, frequency and duration of episodes, and the presence of underlying heart disease. The main goal is to control the ventricular response, interrupt acute episodes, and prevent recurrences.
In patients with symptomatic atrial tachycardia, the first therapeutic strategy aims to reduce the ventricular rate. Options include:
In the presence of haemodynamic instability (hypotension, signs of heart failure), synchronized electrical cardioversion is required.
For the prevention of recurrences, chronic therapy is chosen based on the frequency of episodes and patient tolerability. The main strategies include:
At the same time, it is essential to correct any predisposing factors, such as electrolyte imbalances or thyroid dysfunctions, and to modify lifestyle by reducing caffeine, alcohol, and stimulant drug intake.
The prognosis of atrial tachycardia varies according to the underlying cause and response to treatment. In subjects with healthy hearts, the condition is often benign and can be managed with drug therapy or ablation, with a significant reduction in episodes. However, in incessant forms, chronic elevation of heart rate may lead to tachycardia-induced cardiomyopathy, with progressive deterioration of ventricular function.
In patients with structural heart disease, atrial tachycardia can contribute to the progression of heart failure and increase the risk of progression to atrial fibrillation. Regular monitoring and personalized management are essential to reduce the risk of complications and improve quality of life.
Atrial tachycardia may have a benign course in subjects without structural heart disease, but in persistent forms or in patients with cardiac dysfunction it can lead to significant complications. Prompt management and control of the ventricular response are fundamental to reduce the risk of evolution toward more severe conditions.
The main complications include:
Long-term monitoring and personalized treatment are essential to prevent these complications and improve patient quality of life.